Ureteral stents are essential in routine urologic practice for maintaining urinary drainage and preventing obstruction. Traditional stents are often associated with pain, urinary symptoms, encrustation, infection, and the need for secondary removal procedures. In theory, an “ideal” ureteral stent would address these challenges. This scoping review summarizes contemporary advancements in ureteral stent technology, including innovations in material and design, functional mechanisms, coating systems, and drug elution. An electronic literature search was performed on MEDLINE, EMBASE, Web of Science, and Cochrane Library using MeSH terms from inception to August 2025. Screening and data extraction were performed by two independent reviewers. All studies reporting on technological innovations and advancements in ureteral stent design aimed at improving clinical outcomes and reducing patient morbidity were included. Of the 1407 identified studies, 62 were included in the final review. The included studies were categorized into the following specific categories: stent material, design, and positioning, anti-reflux mechanisms, biodegradable stents, stent removal innovations, stent coatings and drug-eluting systems. Despite substantial advancements in stent technology, no universal “ideal” stent exists. Contemporary advancements in ureteral stent technology span across multiple domains, including innovations in stent material and design, anti-reflux mechanisms, biodegradable systems, stent coatings, and drug-eluting systems. Future ureteral stent development is anticipated to focus on patient-specific customization. Continued translational research and clinical validation are required to integrate many of these ureteral stent innovations into routine urological practice.
This is the second of two articles presenting the European Crohn's and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.
Oculomotor abnormalities are a common finding in neurodegenerative diseases due to degeneration of neural pathways and brain regions involved in controlling eye movements. Pathological changes to the dorsolateral prefrontal cortex, basal ganglia, superior colliculus and cerebellum produce subtle changes in eye-movement metrics that may not be detected by clinical examination. The present review addresses the potential use of eye-movement biomarkers in neurodegenerative conditions such as multiple sclerosis, Parkinson's disease, Alzheimer's disease and other dementias, and amyotrophic lateral sclerosis. Eye-movement metrics such as saccades, anti-saccades, fixation and smooth pursuit are prognostic of disease progression, can differentiate pathologic subtypes as an aid to diagnosis, and enable clinicians to evaluate early worsening of motor and cognitive function. The cost of medical technologies limits their optimal use and accessibility in clinical practice. The shortage of subspecialist neurologists further limits access to care. New eye-tracking technologies incorporated into widely-accessible digital devices such as smart phones and tablets now permit detailed assessments with minimal equipment requirements, providing an important non-invasive and potentially cost-effective method for patient evaluation in routine clinical practice and as an aid to treatment decision-making. Digital biomarkers can be readily employed by healthcare professionals such as family physicians, nurses and pharmacists to bridge the care gaps, potentially providing them with powerful tools that can be broadly adopted to improve the delivery of care to patients with neurodegenerative conditions.
The ability of immunomodulatory mesenchymal stromal cells (MSCs) to improve COVID-19-associated acute respiratory distress syndrome (ARDS) in clinical trials is uncertain. We assessed whether freshly cultured umbilical cord (UC)-derived MSCs improved outcomes in patients with severe COVID-19 ARDS. We enrolled 37 patients with severe COVID-19 ARDS: 15 in the phase 1 dose escalation and open label extension studies (NCT04400032), and 22 patients in the phase 2b randomized clinical trial (NCT04865107). Delivery of up to 270 × 106 MSCs in three divided daily doses was well tolerated and resulted in qualitative improvement in all clinical outcomes. Furthermore, MSCs resulted in resolution of lymphopenia, consistent with an important immunomodulatory effect, with significant improvement in patient reported quality-of-life measures (SF-36) at 6 months pointing to possible durable clinical effects. These findings suggest a potential benefit of freshly cultured, UC-MSCs in severe COVID-19 ARDS, associated with biological evidence of favorable immunomodulatory activity.
Importance:Chronic subdural hematomas commonly recur after surgical drainage. The effect of adjunctive embolization of the middle meningeal artery (EMMA) on recurrence risk remains unclear. Objective:To evaluate whether EMMA as an adjunct to surgical drainage reduces chronic subdural hematoma recurrence compared with surgery alone. Design, Setting, and Participants:This trial was a randomized, open-label, blinded-end point trial involving adults with unilateral, symptomatic chronic subdural hematoma (≥10 mm) undergoing surgical drainage across 9 tertiary care centers in Canada between August 2021 and April 2025. Intervention:EMMA using a liquid embolic agent (Onyx-18) within 72 hours after surgical drainage vs a control group that did not receive EMMA after surgical drainage. Main Outcomes and Measures:Primary outcome was symptomatic recurrence of chronic subdural hematoma detected on computed tomographic (CT) scan at 90 days (range, 60 to 120 days). Secondary outcomes included radiographic recurrence of chronic subdural hematoma, 90-day mortality, and serious adverse events. The last date of follow-up was July 27, 2025. Results:Of 192 randomized participants, 186 (mean age, 71.8 years; 136 male [73%]) completed the trial (93 per group). The primary outcome of symptomatic recurrence of chronic subdural hematoma detected on CT scan occurred in 4 participants (4.3%) in the EMMA group vs 26 patients (28%) in the control group (risk difference, -23.7; 95% CI, -34.1 to -13.9; P < .001). Radiographic recurrence occurred in 13 participants (14%) in the EMMA group vs 46 patients (49.5%) in the control group. Mortality was 4.3% vs 1.1%; serious adverse events occurred in 8.6% vs 5.4%, respectively. Conclusions and Relevance:Adjunctive EMMA after surgical drainage significantly reduced symptomatic recurrence on CT scan of unilateral chronic subdural hematoma at 90 days compared with surgery alone. Trial Registration:ClinicalTrials.gov Identifier: NCT04750200.